Showing 3711-3720 of 8865 results for "".
- Analysis: Air Pollution Linked with Elevated Disease Activity in Bullous Pemphigoidhttps://practicaldermatology.com/news/analysis-air-pollution-linked-with-elevated-disease-activity-in-bullous-pemphigoid/2474733/New retrospective research indicates a relationship between ambient air pollution and increased disease activity in patients with bullous pemphigoid (BP), compared to those with pemphigus. Researchers analyzed 617 clinic visit
- Blended Wavelength Laser Hair Removal Demonstrates Safety and Efficacy Across Skin Toneshttps://practicaldermatology.com/news/blended-wavelength-laser-hair-removal-demonstrates-safety-and-efficacy-across-skin-tones/2474667/New data demonstrates how dual-wavelength laser devices may offer a safer, more inclusive approach to hair removal for all skin tones. At the recent American Society for Laser Medicine and Surgery (ASLMS) annual meeting, Nkemjika Ugonabo, MD, MPH, FAAD, Assistant Professor at Albert Einste
- ElderDerm Co-Director Suggests Alternatives for 'Senile' in Diagnoseshttps://practicaldermatology.com/news/ElderDerm-Co-Director-Suggests-Alternatives-Senile-Diagnoses/2474689/The word senile can be avoided in discussing dermatologic diseases, Jaya Manjunath, MSIV, asserted at the ElderDerm 2025 Conference in Washington, DC. Manjunath, a medical student and co-director of the conference along with Practical Dermatology editorial board member Adam Friedm
- Arcutis Announces Expert Statements on Genital Psoriasishttps://practicaldermatology.com/news/arcutis-announces-expert-statements-on-genital-psoriasis/2474665/Arcutis Biotherapeutics, Inc. has announced new consensus statements aimed at improving the diagnosis and management of genital psoriasis, according to a company press release. The 14 statements, developed by a multidisciplinary group of dermatology and immunology experts with the Genital
- Hair & Scalp Disorders in Focus at Upcoming Virtual CME Conferencehttps://practicaldermatology.com/news/hair-scalp-disorders-in-focus-at-upcoming-virtual-cme-conference/2474649/Organizers have launched a new CME-accredited conference focused on providing dermatologists insights and strategies for treating hair and scalp disorders in diverse populations. Hair & Scalp Disorders: The Rx Pad & Be
- Market for Atopic Dermatitis Treatments to Surge Past $22 Billionhttps://practicaldermatology.com/news/market-for-atopic-dermatitis-treatments-to-surge-past-22-billion/2474524/The global atopic dermatitis (AD) market is projected to more than double over the next decade, reaching $22.37 billion by 2034, new research from Polaris Market Research indicates. Driven by an annual growth rate of 8.5%, the
- Study: Nonprescription Balm Performs on Par with Topical Antibiotichttps://practicaldermatology.com/news/study-nonprescription-balm-performs-on-par-with-topical-antibiotic/2474439/A new randomized controlled trial found that a nonprescription repairing balm containing panthenol, madecassoside, and metal salts (CB5) performs equivalently to a topical antibiotic (PSO) for wound healing after cryotherapy of actinic keratoses (AKs).
- Simvastatin Shows Promise as Adjunct Treatment for Vitiligo in Meta-Analysishttps://practicaldermatology.com/news/simvastatin-shows-promise-as-adjunct-treatment-for-vitiligo-in-meta-analysis/2474442/A new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo, showing significant benefits in repigmentation and disease severity reduction. Vitiligo, an autoimmune disorder marked by melanocyte destruc
- Analysis: Drug Class Influences Clinical Management of Eruptive Keratoacanthoma/Squamous Cell Carcinomahttps://practicaldermatology.com/news/drug-class-influences-clinical-profile-and-management-of-eruptive-kascc/2474440/The clinical features and management of drug-induced eruptive keratoacanthoma (KA) and squamous cell carcinoma (SCC) differ significantly depending on the causative drug class, according to a new analysis of 172 reported cases.
- ARRECTOR: Roflumilast Foam 0.3% Shows Strong Efficacy for Scalp and Body Psoriasishttps://practicaldermatology.com/news/arrector-roflumilast-foam-shows-strong-efficacy-for-scalp-and-body-psoriasis/2474520/A once-daily roflumilast foam formulation significantly improved scalp and body psoriasis in a pivotal phase 3 trial, according to a press release from Arcutis Biotherapeutics, Inc. Researchers for the randomized, double-blin